Background /Aim: Acne fulminans is a rare form of acne vulgaris with acute clinical deterioration including systemic signs. Etiopathogenesis and management remain largely unknown. Our aim is to assess the efficacy of a combined therapeutic regimen of systemic isotretinoin and prednisolone following the recent concepts of acne pathogenesis and drug kinetics. Methods: A prospective case series was recruited over 15 years. Isotretinoin 0.5 mg/kg bw/d (0.25-0-0.25) and prednisolone 30 mg/d (10-10-10) were administered concomitantly with prednisolone being tapered after that time. The overall efficacy was evaluated at month 1 and every month thereafter. Daily drug doses were split to reduce the risk for adverse effects. Results: 26 patients (20 male, 77%) at a mean age of 19 years and a history of acne vulgaris of 3.2 years presented acutely necrotic and ulcerating skin papules (100%), fever (45%), arthralgia (38.5%), leukocytosis (88.5%) and elevated erythrocyte sedimentation rate (100%). After one month of treatment resolution of systemic signs was achieved in all patients and a >50% skin lesion improvement in 17 patients (65%). Conclusion: The concomitant administration of isotretinoin (0.5 mg/kg bw/d, 0.25-0-0.25) and prednisolone 30 mg/d (10-10-10) is able to resolve systemic signs and markedly improve skin lesions in 65% of the patients at one month.

Keywords:
Acne, Acne fulminans, Isotretinoin, Inflammatory disease, Corticosteroids
1.
Pautrier LM: Acné conglobata avec placards végétants et ulcéreux à type de pyodermites végétantes; abcès torpides, placards fibreux - importance anormale des trajets fistulisés sous-cutanés - mort par septicémie avec larges abcès et décollements osseux. Acta Derm Venereol (Stockh) 1937;18:565-574.
2.
Plewig G, Kligman AM: Acne. Springer, Berlin, 1975, p 196.
3.
Karvonen SL: Acne fulminans: report of clinical findings and treatment of twenty-four patients. J Am Acad Dermatol 1993;28:572-579.
4.
Pauli SL, Valkeakari T, Rasanen L, Tuomi ML, Reunala T: Osteomyelitis-like bone lesions in acne fulminans. Eur J Pediatr 1989;149:110-113.
5.
Iqbal M, Kolodney MS: Acne fulminans with synovitis-acne-pustulosis-hyperostosis-osteitis (SAPHO) syndrome treated with infliximab. J Am Acad Dermatol 2005;52:118-120.
6.
Seukeran DC, Cunliffe WJ: The treatment of acne fulminans: a review of 25 cases. Br J Dermatol 1999;141:307-309.
7.
Traupe H, von Mühlendahl KE, Brämswig J, Happle R: Acne of the fulminans type following testosterone therapy in three excessively tall boys. Arch Dermatol 1988;124:414-417.
8.
Kraus SL, Emmert S, Schön MP, Haenssle HA: The dark side of beauty: acne fulminans induced by anabolic steroids in a male bodybuilder. Arch Dermatol 2012;148:1210-1212.
9.
Placzek M, Degitz K, Schmidt H, Plewig G: Acne fulminans in late-onset congenital adrenal hyperplasia. Lancet 1999;354:739-740.
10.
Zouboulis CC, Krieter A, Gollnick H, Mischke D, Orfatios CE: Progressive differentiation of human sebocytes in vitro is characterized by increasing cell size and altering antigen expression and is regulated by culture duration and retinoids. Exp Dermatol 1994;3:151-160.
11.
Nelson AM, Gilliland KL, Cong Z, Thiboutot DM: 13-cis retinoic acid induces apoptosis and cell cycle arrest in human SEB-1 sebocytes. J Invest Dermatol 2006;126:2178-2189.
12.
Thomson KF, Cunliffe WJ: Acne fulminans “sine fulminans.” Clin Exp Dermatol 2000;25:299-301.
13.
Oeff MK, Seltmann H, Hiroi N, Nastos A, Makrantonaki E, Bornstein SR, Zouboulis CC: Differential regulation of Toll-like receptor and CD14 pathways by retinoids and corticosteroids in human sebocytes. Dermatology 2006;213:266.
14.
Roques C, Téot L: The use of corticosteroids to treat keloids: a review. Int J Low Extrem Wounds 2008;7:137-145.
15.
Wakefield L, Kim SJ, Glick A, Winokur T, Colletta A, Sporn M: Regulation of transforming growth factor-beta subtypes by members of the steroid hormone superfamily. J Cell Sci 1990;13(suppl):139-148.
16.
Papakonstantinou E, Aletras AJ, Glass E, Tsogas P, Dionyssopoulos A, Adjaye J, Fimmel S, Gouvousis P, Herwig R, Lehrach H, Zouboulis CC, Karakiulakis G: Matrix metalloproteinases of epithelial origin in facial sebum of patients with acne and their regulation by isotretinoin. J Invest Dermatol 2005;125:673-684.
17.
Orfanos CE, Zouboulis CC, Almond-Roesler B, Geilen CC: Current use and future potential role of retinoids in dermatology. Drugs 1997;53:358-388.
18.
Orfanos CE, Zouboulis CC: Oral retinoids in the treatment of seborrhoea and acne. Dermatology 1998;196:140-147.
19.
Almond-Roesler B, Blume-Peytavi U, Bisson S, Krahn M, Rohloff E, Orfanos CE: Monitoring of isotretinoin therapy by measuring the plasma levels of isotretinoin and 4-oxo-isotretinoin. A useful tool for management of severe acne. Dermatology 1998;196:176-181.
20.
Al-Habet S, Rogers HJ: Pharmacokinetics of intravenous and oral prednisolone. Br J Clin Pharmacol 1980;10:503-508.
© 2017 S. Karger AG, Basel
2017
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.